(-1.57%) 5 035.69 points
(-1.49%) 37 816 points
(-2.04%) 15 658 points
(-0.95%) $81.15
(-2.41%) $1.943
(-0.17%) $2 299.10
(-0.18%) $26.61
(-0.44%) $944.00
(0.11%) $0.938
(0.26%) $11.12
(0.08%) $0.801
(0.00%) $93.45
Live Chart Being Loaded With Signals
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases...
Stats | |
---|---|
今日成交量 | 92 519.00 |
平均成交量 | 75 375.00 |
市值 | 233.56M |
EPS | $-0.420 ( 2024-03-13 ) |
下一个收益日期 | ( $0 ) 2024-05-08 |
Last Dividend | $2.50 ( 2021-07-15 ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.47 |
ATR14 | $0.0350 (0.46%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-03 | Simard John | Buy | 2 470 355 | Convertible Loan Agreement |
2023-06-23 | Waldin Jan-paul | Buy | 25 000 | Director Stock Option |
2023-06-23 | Libby Peter | Buy | 25 000 | Director Stock Option |
2023-06-23 | Macadam Donald H. | Buy | 25 000 | Director Stock Option |
2023-06-23 | Mckenzie W Thorpe | Buy | 25 000 | Director Stock Option |
INSIDER POWER |
---|
97.98 |
Last 100 transactions |
Buy: 4 116 188 | Sell: 11 979 897 |
音量 相关性
XBiotech Inc 相关性 - 货币/商品
XBiotech Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-1.74M (0.00 %) |
EPS: | $-0.810 |
FY | 2023 |
营收: | $0 |
毛利润: | $-1.74M (0.00 %) |
EPS: | $-0.810 |
FY | 2022 |
营收: | $4.01M |
毛利润: | $3.36M (83.77 %) |
EPS: | $-1.080 |
FY | 2021 |
营收: | $18.39M |
毛利润: | $12.57M (68.36 %) |
EPS: | $-0.580 |
Financial Reports:
No articles found.
XBiotech Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $2.50 | 2021-07-15 |
Last Dividend | $2.50 | 2021-07-15 |
Next Dividend | $0 | N/A |
Payout Date | 2021-07-23 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $2.50 | -- |
Avg. Dividend % Per Year | 1.55% | -- |
Score | 0.63 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2021 | $2.50 | 15.50% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -9.37 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.108 | 1.200 | -3.60 | -4.32 | [0 - 0.3] |
returnOnEquityTTM | -0.108 | 1.500 | -2.31 | -3.47 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 33.07 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 32.94 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 32.79 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.615 | 2.00 | -0.205 | -0.410 | [0 - 30] |
freeCashFlowPerShareTTM | -0.627 | 2.00 | -0.314 | -0.627 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.334 | 1.000 | 7.76 | 7.76 | [0.2 - 0.8] |
operatingProfitMarginTTM | -14.32 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.0115 | 0.800 | -3.26 | -2.61 | [0.5 - 2] |
Total Score | -0.390 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -9.62 | 1.000 | -1.073 | 0 | [1 - 100] |
returnOnEquityTTM | -0.108 | 2.50 | -1.487 | -3.47 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.627 | 2.00 | -0.209 | -0.627 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.615 | 2.00 | -0.205 | -0.410 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0806 | 1.500 | -2.80 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -7.15 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.981 |
XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。